29.4 C
New York
Thursday, June 11, 2026

Tag: Nasdaq:LENZ

newssourceFORcompanyinformationcontent1marketreleases

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027 
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027

- A word from our sponsors -

spot_img
HomeTagsNasdaq:LENZ

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers